The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
 
“We also urge that the policy changes made by the final rule, first published in January 2017, remain substantially unchanged,” AHA said today in comments on the proposed rule. 
 
Facing deadlines for responding to a lawsuit brought by the AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems, HRSA Oct. 31 proposed the regulation to change the effective and compliance date to Jan. 1.
 
In its comments, AHA also urged the agency to make pricing information available to 340B hospitals and other participating providers online through a secure website, which is required by the final rule, “available as soon as possible after the effective date.”
 

Related News Articles

Blog
My paternal grandmother was born in 1913 as the youngest of five children and the only girl. She had three sons and no daughters. When I arrived, I was the…
Blog
I was raised by my mother, who was a nurse, and an elder sister, who both prioritized education. During a visit to Kentucky State University, I was inspired to…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…
Headline
A federal court March 8 vacated the National Labor Relations Board’s 2023 rule for determining joint-employer status under the National Labor Relations Act and…
Headline
Hospital and health system leaders March 7 received an email from the AHA and its Institute for Diversity and Health Equity reminding them to participate in…